Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease

Blood

Volumn 119, Issue 19, 2012, Pages 4554-4564

  Tsukamoto, Hiroki ^a   Chernogorova, Petya ^b   Ayata, Korcan ^b   Gerlach, Ulrike V ^b   Rughani, Ankur ^a   Ritchey, Jerry W ^a,c   Ganesan, Jayanthi ^b   Follo, Marie ^b   Zeiser, Robert ^b   Thompson, Linda F ^a   Idzko, Marco ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A2 RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 6;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME DEFICIENCY; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84860538096     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-375899     Document Type: Article

References (50)

1. Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010; 16(2):223-230.
2. Zeiser R, Finke J. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. Eur J Cancer. 2006; 42(11):1601-1611. (Pubitemid 44118775)
3. Wilhelm K, Ganesan J, Müller T, et al. Graftversus-host disease enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16(12): 1434-1438.
4. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-versushost disease. J Mol Med. 2011;89(9):833-845.
5. Robson SC, Sevigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2006;2(2):409-430.
6. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(4):299-309.
7. Resta R, Yamashita Y, Thompson LF. Ectoenzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161:95-109.
8. Thomson LF, Ruedi JM, Glass A, et al. Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5-nucleotidase (CD73). Tissue Antigens. 1990;35(1):9-19. (Pubitemid 20044689)
9. Zimmermann H. 5-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285(2):345-365.
10. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol. 2009;(193):215-269.
11. Blackburn MR. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol Sci. 2003;24(2):66-70. (Pubitemid 36135878)
12. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5-nucleotidase (CD73). Purinergic Signal. 2006;2(2):351-360.
13. Lappas CM, Liu PC, Linden J, Kang EM, Malech HL. AdenosineA2Areceptor activation limits graftversus-host disease after allogenic hematopoietic stem cell transplantation. J Leukoc Biol. 2010;87(2): 345-354.
14. Sevigny CP, Li L, Awad AS, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol. 2007;178(7):4240-4249. (Pubitemid 46492374)
15. Volmer JB, Thompson LF, Blackburn MR. Ecto-5-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycininduced lung injury. J Immunol. 2006;176(7): 4449-4458. (Pubitemid 44264425)
16. Hasegawa T, Bouïs D, Liao H, Visovatti SH, Pinsky DJ. Ecto-5-nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res. 2008; 103(12):1410-1421.
17. Ohtsuka T, Changelian PS, Bouïs D, et al. Ecto-5-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. J Immunol. 2010;185(2):1321-1329.
18. Grenz A, Zhang H, Eckle T, et al. Protective role of ecto-5-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol. 2007;18(3):833-845. (Pubitemid 46434500)
19. Thompson LF, Eltzschig HK, Ibla JC, et al. Crucial role for ecto-5-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004;200(11): 1395-1405. (Pubitemid 39657287)
20. Eckle T, Faigle M, GrenzA, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood. 2008; 111(4):2024-2035. (Pubitemid 351451513)
21. Eckle T, Krahn T, Grenz A, et al. Cardioprotection by ecto-5-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007;115(12):1581-1590. (Pubitemid 46648643)
22. Koszalka P, Ozüyaman B, Huo Y, et al. Targeted disruption of cd73/ecto-5-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res. 2004;95(8):814-821. (Pubitemid 39390584)
23. Takedachi M, Qu D, Ebisuno Y, et al. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol. 2008; 180(9):6288-6296.
24. Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71(8):2892-2900.
25. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010;107(4):1547-1552.
26. Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70(6):2245-2255.
27. Wang L, Fan J, Thompson LF, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest. 2011;121(6):2371-2382.
28. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14(7):1315-1323. (Pubitemid 46965261)
29. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759-770.
30. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4-CD25-Foxp3- regulatory T cells as compared to conventional CD4- T cells. Blood. 2008;111(1):453-462.
31. Zeiser R, Nguyen VH, Hou JZ, et al. Early CD30 signaling is critical for adoptively transferred CD4-CD25-regulatory T cells in prevention of acute graft versus host disease. Blood. 2007; 109(5):2225-2233. (Pubitemid 46348227)
32. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4-CD25-regulatory T cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108(1):390-399. (Pubitemid 43990654)
33. Cooke K, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996; 88(8):3230-3239. (Pubitemid 26357409)
34. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173(9):5467-5475. (Pubitemid 39392131)
35. Ohta A, Lukashev D, Jackson EK, Fredholm BB, Sitkovsky M. 1, 3, 7-Trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J Immunol. 2007;179(11):7431-7438.
36. Zhang F, Thornhill SI, Howe SJ, et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood. 2007; 110(5):1448-1457. (Pubitemid 47443959)
37. Dürr C, Pfeifer D, Claus R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010;70(24): 10170-10181.
38. Dudda JC, Lembo A, Bachtanian E, et al. Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur J Immunol. 2005;35(4):1056-1065. (Pubitemid 40542212)
39. Zeiser R, Youssef S, Baker J, Kambhan N, Steinman L, Negrin RS. Preemptive HMG-CoA reductase inhibition provides acute-graft-versushost disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110(13):4588-4598. (Pubitemid 351377828)
40. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17- T helper cells. Cell. 2006;126(6):1121-1133. (Pubitemid 44380299)
41. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
42. Zheng H, Matte-Martone C, Jain D, McNiff J, Shlomchik WD. Central memory CD8- T cells induce graft-versus-host disease and mediate graft-versus-leukemia. J Immunol. 2009;182(10): 5938-5948.
43. Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol. 2011;186(9):5367-5375.
44. Chadjichristos CE, Scheckenbach KE, van Veen TA, et al. Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation. 2010; 121(1):123-131.
45. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104-107.
46. Schaefer L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol. 2010; 10(2):185-190.
47. Trivedi P, Hematti P. Simultaneous generation of CD34- primitive hematopoietic cells and CD73- mesenchymal stem cells from human embryonic stem cells cocultured with murine OP9 stromal cells. Exp Hematol. 2007;35(1):146-154. (Pubitemid 46014371)
48. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010;16(6): 838-847.
49. Grünewald JK, Ridley AJ. CD73 represses proinflammatory responses in human endothelial cells. J Inflamm. 2010;7(1):10.
50. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2008;113(7):1581-1588.